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Abstract 
We describe a 50-year-old Japanese patient with dermatofibrosarcoma protuberans 
(DFSP) rapidly growing after bilateral adrenalectomy for Cushing’s syndrome that 
reduced the serum level of cortisol from 17.1 to 0.8 mg/dl. It is known that 
glucocorticoids decrease the transcriptions of the COL1A1 gene and the PDGFB gene, 
which is under the direct control of the COL1A1 gene in most DFSP. Therefore, the 
hypersecretion of glucocorticoids in Cushing’s syndrome might suppress the 
development of DFSP. To the best of our knowledge, this is the first case of rapid growth 
of DFSP that may be associated with bilateral adrenalectomy for Cushing’s syndrome. 
 
Introduction 
Dermatofibrosarcoma protuberans (DFSP) is a rare skin sarcoma known for its 
indolent and low metastatic potential. Recently, DFSP has been shown to be characterized 
by a reciprocal translocation, t(17;22)(q22;q13), and a supernumerary ring chromosome 
derived from the translocation r(17;22) [1]. The translocation results in a fusion of two 
genes, COL1A1 and PDGFB [2]. The COL1A1 gene is located at 17q21–22 and encodes 
the a1 (l) chain of type I collagen. The PDGFB gene is located at 22q13 and encodes the B 
chain of the platelet-derived growth factor (PDGF) ligand. The fusion causes a Case Rep Dermatol 2011;3:113–117 
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deregulation of the PDGFB gene by deleting its exon 1 and placing it under the direct 
control of the COL1A1 gene. This rearrangement leads to an unregulated production of 
the growth factor, which seems to play an important role in the development of DFSP [3]. 
Epidemiological studies revealed that more than 95% of DFSP present anomalies on the 
17q22 and 22q13 chromosomal regions, leading to the fusion of the COL1A1 and PDGFB 
genes [4, 5]. In approximately 5% of cases, no COL1A1-PDGFB fusion was found, 
suggesting that other genes might be involved in the DFSP pathogenesis [6]. 
Cushing’s syndrome is characterized by a chronic and excessive exposure to 
endogenous glucocorticoids (GCs). Chronic GC excess has detrimental effects on the 
skin, leading to atrophy and impaired wound healing [7]. Several in vitro studies have 
shown that GCs induce alterations in extracellular matrix homeostasis, such as collagen 
synthesis and the expression of matrix metalloproteinases, leading to a reduction in the 
collagen mass [8–10]. In other words, increased doses of GCs induce a catabolic 
phenotype in skin fibroblasts in vivo and in vitro. 
In this paper, we describe a patient with a rapid onset of DFSP associated with bilateral 
adrenalectomy for Cushing’s syndrome. To our knowledge, there is no English report of 
DFSP associated with bilateral adrenalectomy for Cushing’s syndrome. 
Case Report 
A 50-year-old Japanese woman visited our outpatient clinic with a 20-year history of an 
asymptomatic, about 3 mm in diameter, subcutaneous nodule on her breast. One year before, this 
nodule rapidly enlarged after she underwent bilateral adrenalectomy for Cushing’s syndrome. On her 
initial visit, physical examination revealed a brown-colored, elastic hard, well-demarcated nodule on the 
left side of her breast (fig. 1). The tumor mass was 20 × 18 mm in size. An excisional biopsy showed 
densely packed, monomorphic, plump, spindle cells arranged in a storiform pattern in the central area 
of the tumor nodule and spindle cells infiltrating into the subcutis of the peripheral lesion (fig. 2a, b). 
The tumor cells were positive for CD34 and negative for factor XIIIa (fig. 2c, d), SMA, and S100 (data 
not shown). Based on the above-mentioned findings, we diagnosed this patient as having DFSP. 
Interestingly, the serum levels of cortisol before and after bilateral adrenalectomy were 17.1 and 0.8 
mg/dl, respectively. We excised the tumor with a 3-cm surgical margin of mammary gland tissue. A half 
year after surgical treatment, there was no evidence of local tumor recurrence. 
Discussion 
This case is unique in suggesting an association between DFSP and Cushing’s 
syndrome, and, to the best of our knowledge, this is the first case report of DFSP 
coexisting with Cushing’s syndrome. 
GCs bind to receptors in the cytoplasm to form complexes that translocate into the 
nucleus to regulate downstream targets by binding to glucocorticoid response elements. 
Previously, Mahonen et al. [11] reported that dexamethasone treatment decreased the 
transcription of the COL1A1 gene. Schoepe et al. [12] reported that, in a skin model, the 
inhibition of COL1A1 mRNA expression correlated with the dose and type of GCs (e.g. 
hydrocortisone, prednicarbate, mometasone-17-furoate, and clobetasol-17-propionate). 
Thus, the increase of cortisol in Cushing’s syndrome may suppress the transcription of 
the COL1A1/PDGFB fusion gene in DFSP. In our case, the tumor mass dramatically Case Rep Dermatol 2011;3:113–117 
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enlarged 1 month after bilateral adrenalectomy for Cushing’s syndrome, which was 
coincident with the sudden reduction of serum cortisol (from 17.1 to 0.8 mg/dl). 
Supportive therapy for DFSP is still limited. Kerob et al. [5] assessed the treatment of 
25 cases of nonresectable DFSP patients with imatinib mesylate. In their report, although 
imatinib mesylate targets PDGF-β and can be effective for DFSP, a clinical response was 
achieved in only 36% of cases. The authors concluded that other reagents to treat 
nonresectable DFSP are necessary [5]. Our present report sheds light on the suppressive 
effect of GCs on the development of DFSP, which could lead to therapeutic use of GCs, 
although in vitro studies regarding the effect of GCs on the growth of cultured DFSP are a 
prerequisite. 
 
 
 
 
 
 
Fig. 1. Brown-colored, elastic hard, well-demarcated nodule on the left side of the breast. The tumor 
mass was 35 × 50 mm in size. 
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Fig. 2. Densely packed, monomorphic, plump, spindle cells arranged in a storiform pattern in the 
central area of the tumor nodule, and, in the peripheral lesion, spindle cells diffusely infiltrating around 
the tumor (a, b). Immunohistochemical staining for CD34 (c) and Factor XIIIa (d). a Original 
magnification ×100; b–d original magnification ×400. 
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